Aquestive Therapeutics In... (AQST)
NASDAQ: AQST
· Real-Time Price · USD
5.42
0.22 (4.23%)
At close: Sep 24, 2025, 3:59 PM
5.43
0.23%
After-hours: Sep 24, 2025, 07:55 PM EDT
4.23% (1D)
| Bid | 5.31 |
| Market Cap | 540.54M |
| Revenue (ttm) | 44.13M |
| Net Income (ttm) | -65.04M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -7.86 |
| Forward PE | -8.97 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 5.5 |
| Volume | 1,897,536 |
| Avg. Volume (20D) | 1,962,276 |
| Open | 5.23 |
| Previous Close | 5.20 |
| Day's Range | 5.21 - 5.44 |
| 52-Week Range | 2.12 - 6.00 |
| Beta | 1.82 |
| Ex-Dividend Date | n/a |
About AQST
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AQST
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AQST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAquestive Therapeutics Inc. is scheduled to release its earnings on
Nov 3, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+28.1%
Aquestive Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
4 months ago
-19.65%
Aquestive Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 sales guidance.
3 months ago · seekingalpha.com
Aquestive Therapeutics: Updating The Anaphylm Timeline To ApprovalAnaphylm's FDA approval process is a major catalyst, with a PDUFA date set for January 31, 2026, and potential AdCom or partnership news ahead. Anaphylm offers a needle-free, orally delivered epinephr...